Alm. Brand Group hosts capital markets event and releases new financial targets for 2025
Announcement no. 22/2022
Alm. Brand Group hosts capital markets event and releases new financial targets for 2025
Today, Alm. Brand Group hosts a capital markets event (Capital Markets Update) and in that connection presents business plans and releases new financial targets for 2025.
Since Alm. Brand Group released its financial targets for 2022 at the beginning of 2020, the group has succeeded in enhancing its value creation and has thereby achieved these targets or, through divestment of activities, realised a significant value potential.
New financial targets
As a result of the acquisition of Codan, forging a new and enlarged business, a target has been defined for the combined group to realise a technical result of DKK 2.1 billion including run-offs and to reduce the combined ratio to 84, including a reduction of the expense ratio to 16.
Alm. Brand Group is also introducing a new profitability target defined as the return on tangible equity (RoTE) of more than 50% in 2025.
All financial targets are supported by the realisation of synergies from the acquisition of Codan in a total amount of DKK 600 million in the period towards 2025.
Rasmus Werner Nielsen, CEO of Alm. Brand Group:
“With the combination of Alm. Brand and Codan, we’ve created a new strong Danish non-life insurance group and a solid foundation for growth. Our goal is to double our technical result, significantly improve our combined ratio and achieve the synergies we’ve promised. Our new ambitious financial targets are supported by a sharp focus on profitable growth, lower costs and a successful integration. In order to achieve our high ambitions, we’ll leverage our combined strengths to make it simple and even more relevant to be a customer of Alm. Brand Group, expand our strong partnerships and, not least, maintain a clear focus on claims prevention and sustainability.”
Solvency and distribution
At 30 September 2022, Alm. Brand Group had an SCR ratio of 199%, including funds to cover the remaining restructuring costs related to the integration of Codan. Alm. Brand Group aims to have an SCR ratio of 170% going forward and will, with due consideration thereto, be able to distribute a high proportion of its future earnings to its shareholders. Accordingly, Alm. Brand Group is changing its distribution policy to a payout ratio of at least 80% and expects the distribution in the coming years to be a combination of dividend payments and share buy-backs.
Please direct any questions regarding this announcement to:
Investors and equity analysts:
Head of Investor Relations Senior Investor Relations Officer
Mads Thinggaard Mikael Bo Larsen
Mobile no. +45 2025 5469 Mobile no. +45 5143 8002
VP, Communication & Sustainability
Mobile no. +45 20 32 65 30
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Sodexo and Harris Interactive reveal the results of the first international sustainable food barometer11.12.2023 08:03:00 CET | Press release
Issy-les-Moulineaux, France - December 11th, 2023 An action-oriented barometer: identifying and activating the change levers towards more sustainable diets. Sodexo reveals the results of the first international sustainable food barometer carried out in partnership with the research and opinion polls institute Harris Interactive. Conducted in 2023 among more than 5,000 people in Brazil, France, the United Kingdom and the United States, this exclusive study breaks down the disparities between people's representations of sustainable food and their associated behaviors for the first time. This action-oriented barometer aims to identify the concrete obstacles as well as the levers to induce changes in eating habits and accelerate the shift towards more sustainable diets. Sophie Bellon, Chairwoman of Sodexo’s Board of Directors & Chief Executive Officer: “Operating in 45 countries and serving 80 million consumers every day, Sodexo is a privileged observer of the changes in people's behaviors
Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer11.12.2023 08:00:00 CET | Press release
Veteran MedTech leader and hospital group CEO joins CMR Surgical as global Chief Commercial Officer Massimiliano Colella joins as global Chief Commercial Officer leading CMR Surgical’s commercial and marketing operations to bring Versius to more hospitals around the worldMassimiliano joins CMR at a time of continued expansion as the second largest soft tissue surgical robotics company, with more than 140 Versius installations and more than 15,000 surgical procedures completedFollowing the recent $165 million financing round, CMR continues to pursue its expansion plans and new market regulatory approvals to bring Versius to more hospitals and patients around the world CAMBRIDGE, UK – Monday 11 December 2023, 07:00 (GMT). CMR Surgical (“CMR” or “the Company”), the global surgical robotics business, today announces that Massimiliano Colella has joined the Company as global Chief Commercial Officer. In his role, Massimiliano will oversee CMR’s commercial and marketing operations. Massimili
Azerion simplifies loan structures between Azerion and Principion11.12.2023 07:30:00 CET | Press release
Amsterdam, 11 December 2023 – Azerion Group N.V. ("Azerion") announces that it has today entered into an agreement with Principion Holding B.V. ("Principion") to simplify Azerion's loan structure by settling several loans outstanding between Azerion and Principion (the "Loan Settlement"). The objectives of the Loan Settlement are to simplify Azerion’s capital structure by setting off mutually outstanding unsecured liabilities, whilst at the same time providing Azerion with security against remaining balances. The Loan Settlement also provides Azerion the ability to use any ordinary shares in the capital of Azerion (the "Shares") to be acquired through the Loan Settlement mechanism for value creating purposes for all shareholders without the issuance of new Shares. The Loan Settlement has been approved by Azerion's management board and supervisory board. As at the date of this press release, the aggregate amount due and outstanding under the loans provided by (i) Principion to Azerion i
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio®11.12.2023 07:30:00 CET | Press release
Nyxoah Announces Real World Case Series Demonstrating Positive Results in Treating CCC Patients with Genio® Data presented at the DGSM Conference in Berlin by Dr. Christian Plettenberg on December 8, 2023 Results showed an average AHI decrease of 73% Mont-Saint-Guibert, Belgium – December 11, 2023, 7:30am CET / 1:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced data from a real-world case series evaluating treatment of three complete concentric collapse (CCC) patients with the Genio® hypoglossal nerve stimulation system. The investigator-sponsored case series was presented by Dr. Christian Plettenberg from the Universitätsklinikum Düsseldorf on December 8, 2023. Results showed an average apnea-hypopnea index (AHI) decrease of 73% and Epworth Sleepiness Scale (ESS) decrease of 58%. There were no imp
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis11.12.2023 07:15:00 CET | Press release
Allschwil, Switzerland, December 11, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its license partner Astellas Pharma US, Inc. (“Astellas”) received the approval of Cresemba® (isavuconazole) for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients by the US Food and Drug Administration (FDA). Cresemba for injection is approved for adults and now for pediatric patients 1 year of age and older. Cresemba capsules are approved for adults and now for pediatric patients 6 years of age and older, who weigh 16 kilograms and greater. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We congratulate Astellas on the approval of Cresemba for the use in children who suffer from invasive aspergillosis or mucormycosis. These severe mold infections primarily affect children suffering